Issues

PreTarg-it employs a two-step process for targeted delivery of radioactivity to tumors. First, a bispecific antibody (“Compound 1”) targets a specific tumor antigen with one arm. Once it localizes in the tumor and clears from the bloodstream, a radiolabeled small ligand (“Compound 2”) is administered. The radioligand binds to the antibody’s second arm in the tumor, while unbound radioligand is quickly excreted. This minimizes radioactivity exposure to healthy organs and achieves high therapeutic indexes. See graphical abstract and the full article on page 1219.